Cost of Disease Progression in Patients with Metastatic Breast, Lung, and Colorectal Cancer

The Oncologist
Carolina ReyesMatthew Matasar

Abstract

To reduce health care costs and improve care, payers and physician groups are piloting value-based and episodic or bundled-care payment models in oncology. Disease progression and associated costs may affect these models, particularly if such programs do not account for disease severity and progression risk across patient populations. This study estimated the incremental cost of disease progression in patients diagnosed with metastatic breast cancer (mBC), colorectal cancer (mCRC) and lung cancer (mLC) and compared costs among patients with and without progression. This was a retrospective study using U.S. administrative claims data from commercial and Medicare Advantage health care enrollees with evidence of mBC, mCRC, and mLC and systemic antineoplastic agent use from July 1, 2006, to August 31, 2014. Outcome measures included disease progression, 12-month health care costs, and 3-year cumulative predictive health care costs. Of 5,709 patients with mBC, 3,707 patients with mCRC, and 5,201 patients with mLC, 56.8% of patients with mBC, 58.1% of those with mCRC, and 80.3% of those with mLC patients had evidence of disease progression over 12 months. Among patients with mBC and mCRC, adjusted and unadjusted health care costs wer...Continue Reading

References

Aug 23, 2003·Biostatistics·D Y Lin
Mar 6, 2004·Breast Cancer Research and Treatment·S RaoD Gilden
Feb 9, 2006·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·N BerkowitzG Silberman
Mar 16, 2006·BJU International·Navid BerdjisManfred P Wirth
Jun 27, 2006·Clinical Colorectal Cancer·L Clark ParamoreKathy H Fraeman
Jan 24, 2007·Cancer Control : Journal of the Moffitt Cancer Center·Arti Hurria, Stuart M Lichtman
Jul 2, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joan L WarrenMartin L Brown
Aug 30, 2008·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Yu-Mei GuEn-Hua Wang
Nov 27, 2010·Journal of Medical Economics·Xue SongSue Gao
Jan 14, 2011·Journal of the National Cancer Institute·Angela B MariottoMartin L Brown
Sep 3, 2011·Journal of Oncology Practice·Xue SongSue Gao
Nov 15, 2011·BMC Health Services Research·Montserrat Vera-LlonchGerry Oster
Jun 29, 2013·Journal of Managed Care Pharmacy : JMCP·Brian S SealCarl V Asche
Nov 19, 2013·Journal of Comparative Effectiveness Research·Saurabh RayPamela Landsman-Blumberg
May 20, 2014·Journal of Oncology Practice·Lee N Newcomer
Jul 10, 2014·Journal of Oncology Practice·Lee N NewcomerMonica Perkins

❮ Previous
Next ❯

Citations

May 2, 2020·Annals of Surgery·Sue J FuRahim Nazerali
Jul 18, 2020·Annals of Surgery·Sue J FuRahim Nazerali
Oct 2, 2020·International Journal of Radiation Oncology, Biology, Physics·Abhishek KumarJames D Murphy
Jul 3, 2021·Frontiers in Oncology·Dirk MehrensWolfgang G Kunz
Jul 3, 2021·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Volkmar MuellerKaren Gelmon

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.